1. Targeting the non-ATP-binding pocket of the MAP kinase p38γ mediates a novel mechanism of cytotoxicity in cutaneous T-cell lymphoma (CTCL)
- Author
-
Chih-Hong Chen, Xu Hannah Zhang, David Horne, Hongzhi Li, Steven T. Rosen, Sangkil Nam, Xiwei Wu, Jack Shively, Jack Hsiang, and Weidong Hu
- Subjects
MAPK/ERK pathway ,Skin Neoplasms ,Biophysics ,Antineoplastic Agents ,Biochemistry ,Peripheral blood mononuclear cell ,Article ,computational virtual screening of chemicals ,NMR spectroscopy ,Adenosine Triphosphate ,Mitogen-Activated Protein Kinase 12 ,TCR signaling pathway ,Structural Biology ,Genetics ,medicine ,Cytotoxic T cell ,Humans ,cutaneous T-cell lymphoma ,Protein kinase A ,Cytotoxicity ,Molecular Biology ,Regulation of gene expression ,biology ,ATP-binding pocket ,Chemistry ,the MAP kinase p38γ ,Cutaneous T-cell lymphoma ,Cell Biology ,medicine.disease ,Lymphoma, T-Cell, Cutaneous ,Gene Expression Regulation, Neoplastic ,Mitogen-activated protein kinase ,Cancer research ,biology.protein ,cytotoxicity ,lipid-binding domain ,TNF alpha ,Signal Transduction - Abstract
We describe here for the first time a lipid-binding-domain (LBD) in p38γ mitogen-activated protein kinase (MAPK) involved in the response of T cells to a newly identified inhibitor, CSH71. We describe how CSH71, which binds to both the LBD and the ATP-binding pocket of p38γ, is selectively cytotoxic to CTCL Hut78 cells but spares normal healthy peripheral blood mononuclear (PBMC) cells, and propose possible molecular mechanisms for its action. p38γ is a key player in CTCL development, and we expect that the ability to regulate its expression by specifically targeting the lipid-binding domain will have important clinical relevance. Our findings characterize novel mechanisms of gene regulation in T lymphoma cells and validate the use of computational screening techniques to identify inhibitors for therapeutic development.
- Published
- 2021